FX.co ★ Viatris Reports Phase 2b CARE Study Data For Cenerimod - Quick Facts

Viatris Inc. (VTRS) has released the findings from its Phase 2b CARE study, which assessed the efficacy and safety of cenerimod in adults suffering from moderate to severe systemic lupus erythematosus (SLE). The study results indicated that a 4 mg dose of cenerimod provided a clinically significant and sustained improvement in various measures of SLE disease activity from baseline, in comparison to a placebo, in conjunction with existing SLE therapies. Cenerimod was well tolerated, with an adverse event profile aligning with its mechanism of action.

The CARE study was conducted as a double-blind, randomized, placebo-controlled Phase 2b trial, involving adult participants aged 18 to 75 years who have moderate-to-severe SLE.